Press "Enter" to skip to content

Alzheimer’s Disease Diagnostics and Therapeutics Market 2019 Significant Growth Rate by Industry Size, Share, Market Dynamics, Development Status of Key Players Forecast to 2024

Alzheimer’s

The “Alzheimer’s Disease Diagnostics and Therapeutics Market” 2019 report provides market size (value and volume), market share, growth rate by types, applications, and combines both qualitative and quantitative methods to make micro and macro forecasts in different regions or countries. Alzheimer’s Disease Diagnostics and Therapeutics Market report also aims to provide useful and comprehensive insights into current market trends and future growth scenarios. Alzheimer’s Disease Diagnostics and Therapeutics market report contains information like SWOT analysis, business highlights, strength, weakness, threats and opportunities of industry.

Top Manufacturers of Alzheimer’s Disease Diagnostics and Therapeutics Market Are:

  • F. Hoffmann
  • La Roche
  • Novartis AG
  • Merck & Co. Inc
  • Pfizer Inc
  • Eisai Co. Ltd
  • Biogen Inc
  • Johnson & Johnson
  • Eli Lilly & Company
  • Amarantus Bioscience Holdings Inc
  • Diagenic ASA
  • Navidea Biopharmaceuticals
  • GE Healthcare

    Get a Sample Copy of the Report – https://www.industryresearch.co/enquiry/request-sample/14245691

    Market Overview:

  • The global Alzheimer’s disease diagnostics and therapeutics market was valued at USD 7,537.4 million in 2018, and is estimated to be valued at USD 11,138.2 million in 2024, witnessing a CAGR of 6.7%. The key factors propelling the growth of this market are investment in biomarkers for drug development, increasing pipeline drug development, increasing sophisticated diagnostics for early detection, along with more precise drug development, and emerging novel diagnostics technologies.
  • Alzheimer’s disease is one of the most prevalent types of dementia that occurs worldwide. According to the Alzheimer’s disease facts and figures, it is estimated that in every 33 seconds, a new case of Alzheimer’s disease occurs, leading to high prevalence of the disease, of almost 35 million patients, around the world. The development of clinical diagnostics and therapeutics for Alzheimer’s disease (AD) and other neurodegenerative conditions is becoming very important. In about 10-15% cases, the clinical diagnosis of AD is inaccurate. So, certain biomarkers that may improve the accuracy of the diagnosis are used. Biomarkers are neurochemical indicators used to determine the risk or prevalence of the disease.
  • Investing in biomarkers for drug development and early detection of AD acts as a major driver, and fuels the growth of the Alzheimer’s disease diagnostics and therapeutics market, globally.

    Scope of the Report:

  • As per the , Alzheimer’s disease (AD) is a progressive, degenerative disorder that attacks the brain’s nerve cells or neurons, resulting in loss of memory, thinking and language skills, and behavioural changes.

    Alzheimer’s Disease Diagnostics and Therapeutics Market Report Answers the Following Questions:

    • What will the market size and the growth rate be in 2024?
    • What are the key factors driving the global Alzheimer’s Disease Diagnostics and Therapeutics market?
    • What are the key market trends impacting the growth of the global Alzheimer’s Disease Diagnostics and Therapeutics market?
    • What are the challenges to market growth?
    • Who are the key vendors in the global Alzheimer’s Disease Diagnostics and Therapeutics market?
    • What are the market opportunities and threats faced by the vendors in the global Alzheimer’s Disease Diagnostics and Therapeutics market?
    • Trending factors influencing the market shares of the relevant regions.
    • What are the key outcomes of the five forces analysis of the global Alzheimer’s Disease Diagnostics and Therapeutics market?

    For More Information or Query or Customization Before Buying, Visit at – https://www.industryresearch.co/enquiry/pre-order-enquiry/14245691

    Key Market Trends:

    Cholinesterase Inhibitors are Expected to hold the Highest Market Share in the Therapeutics Segment

    In the therapeutics segment of the Alzheimer’s disease diagnostics and therapeutics market. Cholinesterase inhibitors are believed to have the largest market size and are expected to witness a CAGR of 6.4% during the forecast period.

    Cholinesterase inhibitors are used for the treatment of Alzheimer’s. These cholinesterase inhibitors are approved by the US FDA. Most physicians and perhaps most patients consider cholinergic drugs. Donepezil, galantamine, and rivastigmine are the generic names of cholinesterase inhibitors, which are likely to be the first-line pharmacotherapy choice for mild to moderate Alzheimer’s disease. These drugs have somewhat different pharmacological properties, but all of them work by the same mechanism, which involves inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase.

    The market is dominated by leading brands, such as Aricept, Exelon, and Reminyl; Aricept, whose active ingredient is a cholinesterase inhibitor, holds the largest market share. Several clinical trials are ongoing on cholinesterase inhibitors to increase drug efficacy and decrease adverse effects. Hence, oeing to the developments, the cholinesterase inhibitor drugs market is expected to grow during the forecast period.

    North America Dominates the Market and Expected to do Same in the Forecast Period

    North America currently dominates the market for Alzheimer’s disease diagnostics and therapeutics ,and is expected to continue its stronghold for a few more years. The United States holds the largest share of the global Alzheimer’s disease diagnostics and therapeutics market. According to the Alzheimer’s Association, more than 5 million Americans suffer from Alzheimer’s, as of 2017. The United States is considered to be the global leader in Alzheimer’s disease intervention and management. America has a large pool of biopharmaceutical companies, which cumulatively have 85 drugs for combating Alzheimer’s disease in various stages of the pipeline. Hence, the market is expected to register a healthy CAGR over the forecast period.

    Market Dynamics: –

    • Drivers: (Developing regions and growing markets)
    • Limitations: (Regional, Key Player facing Issues, Future Barriers for growth)
    • Opportunities: (Regional, Growth Rate, Competitive, Consumption)

    The report provides key statistics on the market status of the Alzheimer’s Disease Diagnostics and Therapeutics Market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Alzheimer’s Disease Diagnostics and Therapeutics.

    Purchase this Report (Price 4250 USD for single user license) – https://www.industryresearch.co/purchase/14245691

    Report Objectives:

    • Analyzing the size of the Alzheimer’s Disease Diagnostics and Therapeutics market on the basis of value and volume.
    • Accurately calculating the market segments, consumption, and other dynamic factors of different sections of the global Alzheimer’s Disease Diagnostics and Therapeutics market.
    • Determining the key dynamics of the Alzheimer’s Disease Diagnostics and Therapeutics market.
    • Highlighting significant trends of the Alzheimer’s Disease Diagnostics and Therapeutics market in terms of manufacture, revenue, and sales.
    • Deeply summarizing top players of the Alzheimer’s Disease Diagnostics and Therapeutics market and showing how they compete in the industry.
    • Studying industry processes and costs, product pricing, and various trends related to them.
    • Displaying the performance of different regions and countries in the global Alzheimer’s Disease Diagnostics and Therapeutics market.

    Detailed TOC of Alzheimer’s Disease Diagnostics and Therapeutics Market Report 2019-2024:

    1 INTRODUCTION
    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study

    2 RESEARCH METHODOLOGY

    3 EXECUTIVE SUMMARY

    4 MARKET DYNAMICS
    4.1 Market Overview
    4.2 Market Drivers
    4.2.1 Investment in Biomarkers for Drug Development
    4.2.2 Increasing Pipeline Drug Development
    4.2.3 Increasing Sophisticated Diagnostics for Early Detection and More Precise Drug Development
    4.2.4 Emerging Novel Diagnostic Technologies
    4.3 Market Restraints
    4.3.1 Early Diagnosis of the Indication is Challenging
    4.3.2 Decline in the Market Due to Failures of Late-stage Drugs
    4.3.3 Lack of Surrogate Markers for Drug Discovery and Drug Development
    4.3.4 Insufficient Research Funding and Lengthy, Expensive, and Uncertain Process
    4.4 Porter’s Five Forces Analysis
    4.4.1 Threat of New Entrants
    4.4.2 Bargaining Power of Buyers/Consumers
    4.4.3 Bargaining Power of Suppliers
    4.4.4 Threat of Substitute Products and Services
    4.4.5 Intensity of Competitive Rivalry

    5 MARKET SEGMENTATION
    5.1 By Therapeutics
    5.1.1 Cholinesterase Inhibitors
    5.1.2 NMDA Receptor Antagonists
    5.1.3 Other Therapeutics
    5.2 By Diagnostics
    5.2.1 Brain Imaging
    5.2.2 CFS Test for Alzheimer’s Disease
    5.3 Geography
    5.3.1 North America
    5.3.1.1 United States
    5.3.1.2 Canada
    5.3.1.3 Mexico
    5.3.2 Europe
    5.3.2.1 Germany
    5.3.2.2 United Kingdom
    5.3.2.3 France
    5.3.2.4 Italy
    5.3.2.5 Spain
    5.3.2.6 Rest of Europe
    5.3.3 Asia-Pacific
    5.3.3.1 China
    5.3.3.2 Japan
    5.3.3.3 India
    5.3.3.4 Australia
    5.3.3.5 South Korea
    5.3.3.6 Rest of Asia-Pacific
    5.3.4 Middle East & Africa
    5.3.4.1 GCC
    5.3.4.2 South Africa
    5.3.4.3 Rest of Middle East & Africa
    5.3.5 South America
    5.3.5.1 Brazil
    5.3.5.2 Argentina
    5.3.5.3 Rest of South America

    6 COMPETITIVE LANDSCAPE
    6.1 Company Profiles
    6.1.1 F. Hoffmann-La Roche
    6.1.2 Novartis AG
    6.1.3 Merck & Co. Inc
    6.1.4 Pfizer Inc
    6.1.5 Eisai Co. Ltd
    6.1.6 Biogen Inc
    6.1.7 Johnson & Johnson
    6.1.8 Eli Lilly & Company
    6.1.9 Amarantus Bioscience Holdings Inc
    6.1.10 Diagenic ASA
    6.1.11 Navidea Biopharmaceuticals
    6.1.12 GE Healthcare

    7 MARKET OPPORTUNITIES AND FUTURE TRENDS

     

    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Electric Guitar Industry: Global Market Overview, Shares, Growth, Demand, market Size, Production, Types & Applications and Forecast Report 2024

    Flooring Underlayment Market Share, Size 2019 – Global Industry Future Demand, Worldwide Research, Top Leading Players, Emerging Trends, Region by Forecast to 2024

    Slimming Food Ingredients Market 2019 Global Industry Leading Players Update, Gross Margin Analysis, Size, Development History, Business Prospect and Industry Research Report 2025

    Cannabis Testing Equipment Market Size & Share 2019 – 2023 Business Strategy, Development Plans, Global Growth Rate by Manufacturers, and Forecast Analysis till 2023